U.S. Food and Drug Administration Accepts for Priority Review Bristol Myers Squibb's Application for Orencia (abatacept) for the Prevention of Acute Graft Versus Host Disease (aGvHD)Business Wire • 08/23/21
U.S. Food and Drug Administration Approves Opdivo® (nivolumab) for the Adjuvant Treatment of Patients with High-Risk Urothelial CarcinomaBusiness Wire • 08/20/21
Bristol Myers Squibb Receives European Commission Approval for Abecma (Idecabtagene Vicleucel), the First Anti-BCMA CAR T Cell Therapy for Relapsed and Refractory Multiple MyelomaBusiness Wire • 08/19/21
3 Stocks Warren Buffett Is Selling That You Should Be Buying Hand Over FistThe Motley Fool • 08/18/21
Got $100? Here Are 3 Top Dividend Growth Stocks to Jump-Start Your PortfolioThe Motley Fool • 08/17/21
EMA Validates Bristol Myers Squibb's Applications for Opdivo (nivolumab) + Yervoy (ipilimumab) and Opdivo + Chemotherapy as First-Line Treatments for Unresectable Advanced, Recurrent or Metastatic Esophageal Squamous Cell CarcinomaBusiness Wire • 08/17/21
Apple, GM, Kroger, AbbVie, Merck, Bristol Myers Squibb, Biogen — How Warren Buffett's Berkshire Adjusted Its Portfolio In Q2Benzinga • 08/17/21
Bristol Myers Squibb and Five Leading Historically Black Colleges and Universities Launch Tomorrow's Innovators to Create Custom Biopharma Educational Programming and Increase Recruitment of Black Talent in the Biopharma IndustryBusiness Wire • 08/10/21
